These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16817978)

  • 21. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Walker D; Kelly C; Birrell F; Chakravarty K; Maddison P; Heslin M; Patel A; Kingsley GH
    BMJ; 2015 Mar; 350():h1046. PubMed ID: 25769495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.
    Wijbrandts CA; Dijkgraaf MG; Kraan MC; Vinkenoog M; Smeets TJ; Dinant H; Vos K; Lems WF; Wolbink GJ; Sijpkens D; Dijkmans BA; Tak PP
    Ann Rheum Dis; 2008 Aug; 67(8):1139-44. PubMed ID: 18055470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M; Creemers MC; van Riel PL
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment.
    Toh ML; Marotte H; Blond JL; Jhumka U; Eljaafari A; Mougin B; Miossec P
    Arthritis Rheum; 2006 Jul; 54(7):2109-18. PubMed ID: 16802346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
    Stuhlmüller B; Häupl T; Hernandez MM; Grützkau A; Kuban RJ; Tandon N; Voss JW; Salfeld J; Kinne RW; Burmester GR
    Clin Pharmacol Ther; 2010 Mar; 87(3):311-21. PubMed ID: 20032971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab).
    Buch MH; Reece RJ; Quinn MA; English A; Cunnane G; Henshaw K; Bingham SJ; Bejarano V; Isaacs J; Emery P
    Rheumatology (Oxford); 2008 Oct; 47(10):1469-75. PubMed ID: 18660510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
    Buch MH; Bingham SJ; Bryer D; Emery P
    Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
    Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
    Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis.
    Kvalvik AG; Lefsaker L; Dyvik S; Brun JG
    Joint Bone Spine; 2007 Dec; 74(6):606-11. PubMed ID: 17900958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
    Saleem B; Mackie S; Quinn M; Nizam S; Hensor E; Jarrett S; Conaghan PG; Emery P
    Ann Rheum Dis; 2008 Aug; 67(8):1178-80. PubMed ID: 18234715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
    Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semi-quantitative analysis of rheumatoid finger joint synovitis using power Doppler ultrasonography: when to perform follow-up study after treatment consisting mainly of antitumor necrosis factor alpha agent.
    Kamishima T; Sagawa A; Tanimura K; Shimizu M; Matsuhashi M; Shinohara M; Hagiwara H; Henmi M; Narita A; Terae S; Shirato H
    Skeletal Radiol; 2010 May; 39(5):457-65. PubMed ID: 19936743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis.
    Toonen EJ; Gilissen C; Franke B; Kievit W; Eijsbouts AM; den Broeder AA; van Reijmersdal SV; Veltman JA; Scheffer H; Radstake TR; van Riel PL; Barrera P; Coenen MJ
    PLoS One; 2012; 7(3):e33199. PubMed ID: 22457743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.
    Sidiropoulos P; Bertsias G; Kritikos HD; Kouroumali H; Voudouris K; Boumpas DT
    Ann Rheum Dis; 2004 Feb; 63(2):144-8. PubMed ID: 14722202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.